Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance

Shih Min A Huang, Anlai Wang, Rita Greco, Zhifang Li, Claude Barberis, Michel Tabart, Vinod Patel, Laurent Schio, Raelene Hurley, Hong Cheng, Christoph Lengauer, Jack Pollard, James Watters, Carlos Garcia-Echeverria, Dmitri Wiederschain, Francisco Adrian, JingXin Zhang

Research output: Contribution to journalArticle

Abstract

Inhibitors of JAK2 kinase are emerging as an important treatment modality for myeloproliferative neoplasms (MPN). However, similar to other kinase inhibitors, resistance to JAK2 inhibitors may eventually emerge through a variety of mechanisms. Effective drug combination is one way to enhance therapeutic efficacy and combat resistance against JAK2 inhibitors. To identify potential combination partners for JAK2 compounds in MPN cell lines, we performed pooled shRNA screen targeting 5,000 genes in the presence or absence of JAK2 blockade. One of the top hits identified was MYC, an oncogenic transcription factor that is difficult to inhibit directly, but could be targeted by modulation of upstream regulatory elements such as kinases. We demonstrate herein that PIM kinase inhibitors efficiently suppress MYC protein levels in MPN cell lines. Importantly, overexpression of MYC restores the viability of PIM inhibitor-treated cells, revealing causal relationship between MYC down-regulation and cell growth inhibition by PIM compounds. Combination of various PIM inhibitors with a JAK2 inhibitor results in significant synergistic growth inhibition of multiple MPN cancer cell lines and induction of apoptosis. Mechanistic studies revealed strong downregulation of phosphorylated forms of S6 and 4EBP1 by JAK2/PIM inhibitor combination treatment. Finally, such combination was effective in eradicating in vitro JAK2 inhibitor-resistant MPN clones, where MYC is consistently up-regulated. These findings demonstrate that simultaneous suppression of JAK2 and PIM kinase activity by small molecule inhibitors is more effective than either agent alone in suppressing MPN cell growth. Our data suggest that JAK2 and PIM combination might warrant further investigation for the treatment of JAK2-driven hematologic malignancies.

Original languageEnglish (US)
Pages (from-to)3362-3374
Number of pages13
JournalOncotarget
Volume5
Issue number10
StatePublished - 2014
Externally publishedYes

Fingerprint

Drug Resistance
Cell Proliferation
Phosphotransferases
Neoplasms
Cell Line
Down-Regulation
Growth
S 6
Hematologic Neoplasms
Drug Combinations
Small Interfering RNA
Transcription Factors
Clone Cells
Apoptosis
Genes
Proteins

Keywords

  • Drug combination
  • JAK2
  • MYC
  • Myeloproliferative neoplasms
  • PIM
  • Pooled shRNA screen

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Huang, S. M. A., Wang, A., Greco, R., Li, Z., Barberis, C., Tabart, M., ... Zhang, J. (2014). Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance. Oncotarget, 5(10), 3362-3374.

Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance. / Huang, Shih Min A; Wang, Anlai; Greco, Rita; Li, Zhifang; Barberis, Claude; Tabart, Michel; Patel, Vinod; Schio, Laurent; Hurley, Raelene; Cheng, Hong; Lengauer, Christoph; Pollard, Jack; Watters, James; Garcia-Echeverria, Carlos; Wiederschain, Dmitri; Adrian, Francisco; Zhang, JingXin.

In: Oncotarget, Vol. 5, No. 10, 2014, p. 3362-3374.

Research output: Contribution to journalArticle

Huang, SMA, Wang, A, Greco, R, Li, Z, Barberis, C, Tabart, M, Patel, V, Schio, L, Hurley, R, Cheng, H, Lengauer, C, Pollard, J, Watters, J, Garcia-Echeverria, C, Wiederschain, D, Adrian, F & Zhang, J 2014, 'Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance', Oncotarget, vol. 5, no. 10, pp. 3362-3374.
Huang SMA, Wang A, Greco R, Li Z, Barberis C, Tabart M et al. Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance. Oncotarget. 2014;5(10):3362-3374.
Huang, Shih Min A ; Wang, Anlai ; Greco, Rita ; Li, Zhifang ; Barberis, Claude ; Tabart, Michel ; Patel, Vinod ; Schio, Laurent ; Hurley, Raelene ; Cheng, Hong ; Lengauer, Christoph ; Pollard, Jack ; Watters, James ; Garcia-Echeverria, Carlos ; Wiederschain, Dmitri ; Adrian, Francisco ; Zhang, JingXin. / Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance. In: Oncotarget. 2014 ; Vol. 5, No. 10. pp. 3362-3374.
@article{23c43139a2534fa69776bc6ac71637f0,
title = "Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance",
abstract = "Inhibitors of JAK2 kinase are emerging as an important treatment modality for myeloproliferative neoplasms (MPN). However, similar to other kinase inhibitors, resistance to JAK2 inhibitors may eventually emerge through a variety of mechanisms. Effective drug combination is one way to enhance therapeutic efficacy and combat resistance against JAK2 inhibitors. To identify potential combination partners for JAK2 compounds in MPN cell lines, we performed pooled shRNA screen targeting 5,000 genes in the presence or absence of JAK2 blockade. One of the top hits identified was MYC, an oncogenic transcription factor that is difficult to inhibit directly, but could be targeted by modulation of upstream regulatory elements such as kinases. We demonstrate herein that PIM kinase inhibitors efficiently suppress MYC protein levels in MPN cell lines. Importantly, overexpression of MYC restores the viability of PIM inhibitor-treated cells, revealing causal relationship between MYC down-regulation and cell growth inhibition by PIM compounds. Combination of various PIM inhibitors with a JAK2 inhibitor results in significant synergistic growth inhibition of multiple MPN cancer cell lines and induction of apoptosis. Mechanistic studies revealed strong downregulation of phosphorylated forms of S6 and 4EBP1 by JAK2/PIM inhibitor combination treatment. Finally, such combination was effective in eradicating in vitro JAK2 inhibitor-resistant MPN clones, where MYC is consistently up-regulated. These findings demonstrate that simultaneous suppression of JAK2 and PIM kinase activity by small molecule inhibitors is more effective than either agent alone in suppressing MPN cell growth. Our data suggest that JAK2 and PIM combination might warrant further investigation for the treatment of JAK2-driven hematologic malignancies.",
keywords = "Drug combination, JAK2, MYC, Myeloproliferative neoplasms, PIM, Pooled shRNA screen",
author = "Huang, {Shih Min A} and Anlai Wang and Rita Greco and Zhifang Li and Claude Barberis and Michel Tabart and Vinod Patel and Laurent Schio and Raelene Hurley and Hong Cheng and Christoph Lengauer and Jack Pollard and James Watters and Carlos Garcia-Echeverria and Dmitri Wiederschain and Francisco Adrian and JingXin Zhang",
year = "2014",
language = "English (US)",
volume = "5",
pages = "3362--3374",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "10",

}

TY - JOUR

T1 - Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance

AU - Huang, Shih Min A

AU - Wang, Anlai

AU - Greco, Rita

AU - Li, Zhifang

AU - Barberis, Claude

AU - Tabart, Michel

AU - Patel, Vinod

AU - Schio, Laurent

AU - Hurley, Raelene

AU - Cheng, Hong

AU - Lengauer, Christoph

AU - Pollard, Jack

AU - Watters, James

AU - Garcia-Echeverria, Carlos

AU - Wiederschain, Dmitri

AU - Adrian, Francisco

AU - Zhang, JingXin

PY - 2014

Y1 - 2014

N2 - Inhibitors of JAK2 kinase are emerging as an important treatment modality for myeloproliferative neoplasms (MPN). However, similar to other kinase inhibitors, resistance to JAK2 inhibitors may eventually emerge through a variety of mechanisms. Effective drug combination is one way to enhance therapeutic efficacy and combat resistance against JAK2 inhibitors. To identify potential combination partners for JAK2 compounds in MPN cell lines, we performed pooled shRNA screen targeting 5,000 genes in the presence or absence of JAK2 blockade. One of the top hits identified was MYC, an oncogenic transcription factor that is difficult to inhibit directly, but could be targeted by modulation of upstream regulatory elements such as kinases. We demonstrate herein that PIM kinase inhibitors efficiently suppress MYC protein levels in MPN cell lines. Importantly, overexpression of MYC restores the viability of PIM inhibitor-treated cells, revealing causal relationship between MYC down-regulation and cell growth inhibition by PIM compounds. Combination of various PIM inhibitors with a JAK2 inhibitor results in significant synergistic growth inhibition of multiple MPN cancer cell lines and induction of apoptosis. Mechanistic studies revealed strong downregulation of phosphorylated forms of S6 and 4EBP1 by JAK2/PIM inhibitor combination treatment. Finally, such combination was effective in eradicating in vitro JAK2 inhibitor-resistant MPN clones, where MYC is consistently up-regulated. These findings demonstrate that simultaneous suppression of JAK2 and PIM kinase activity by small molecule inhibitors is more effective than either agent alone in suppressing MPN cell growth. Our data suggest that JAK2 and PIM combination might warrant further investigation for the treatment of JAK2-driven hematologic malignancies.

AB - Inhibitors of JAK2 kinase are emerging as an important treatment modality for myeloproliferative neoplasms (MPN). However, similar to other kinase inhibitors, resistance to JAK2 inhibitors may eventually emerge through a variety of mechanisms. Effective drug combination is one way to enhance therapeutic efficacy and combat resistance against JAK2 inhibitors. To identify potential combination partners for JAK2 compounds in MPN cell lines, we performed pooled shRNA screen targeting 5,000 genes in the presence or absence of JAK2 blockade. One of the top hits identified was MYC, an oncogenic transcription factor that is difficult to inhibit directly, but could be targeted by modulation of upstream regulatory elements such as kinases. We demonstrate herein that PIM kinase inhibitors efficiently suppress MYC protein levels in MPN cell lines. Importantly, overexpression of MYC restores the viability of PIM inhibitor-treated cells, revealing causal relationship between MYC down-regulation and cell growth inhibition by PIM compounds. Combination of various PIM inhibitors with a JAK2 inhibitor results in significant synergistic growth inhibition of multiple MPN cancer cell lines and induction of apoptosis. Mechanistic studies revealed strong downregulation of phosphorylated forms of S6 and 4EBP1 by JAK2/PIM inhibitor combination treatment. Finally, such combination was effective in eradicating in vitro JAK2 inhibitor-resistant MPN clones, where MYC is consistently up-regulated. These findings demonstrate that simultaneous suppression of JAK2 and PIM kinase activity by small molecule inhibitors is more effective than either agent alone in suppressing MPN cell growth. Our data suggest that JAK2 and PIM combination might warrant further investigation for the treatment of JAK2-driven hematologic malignancies.

KW - Drug combination

KW - JAK2

KW - MYC

KW - Myeloproliferative neoplasms

KW - PIM

KW - Pooled shRNA screen

UR - http://www.scopus.com/inward/record.url?scp=84902119160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902119160&partnerID=8YFLogxK

M3 - Article

C2 - 24830942

AN - SCOPUS:84902119160

VL - 5

SP - 3362

EP - 3374

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 10

ER -